Revenue Performance - Total revenue for the six months ended June 30, 2022, decreased significantly, with a year-on-year decline of 49.2% in medical conference services revenue and 80.8% in patient education and self-testing services revenue[10]. - The company's revenue decreased by approximately 49.2% from RMB 339.8 million for the six months ended June 30, 2021, to RMB 172.5 million for the six months ended June 30, 2022[24]. - Revenue from medical conference services dropped by about 46.6% from RMB 208.5 million to RMB 111.3 million, primarily due to short-term lockdowns caused by COVID-19 in several provinces of China[25]. - Patient education and self-testing services revenue fell by about 80.8% from RMB 74.3 million to RMB 14.3 million, also due to short-term lockdowns[28]. - The company reported a total revenue of RMB 200 million for the six months ended June 30, 2022, compared to RMB 124.81 million from the global offering in 2021[153]. Customer and User Growth - The number of registered doctors reached 384,965, with online doctor education activities totaling 46,518 sessions and online patient education activities reaching 25,687 sessions by June 30, 2022[14]. - The number of registered patients increased by 321.2% to 200,545 compared to June 30, 2021, while registered doctors grew by 69.9%[14]. Digital Marketing and Product Development - The company plans to enhance its digital marketing business scale in the second half of 2022, focusing on providing precise and efficient digital medical and marketing solutions to new customer groups[16]. - The company aims to optimize its products and services in response to the rise of the domestic innovative biopharmaceutical industry, particularly expanding its business in oncology and chronic kidney disease[19]. - The company has developed multiple digital marketing platforms and products, including the Giraffe Smart Medical Platform and Digital Patient Management Platform, to support its digital marketing initiatives[14]. - The company continues to explore and optimize its internet healthcare platform and business model, focusing on enhancing user privacy and information security through blockchain technology[21]. Financial Performance and Losses - The company recorded a net loss of approximately RMB 48.2 million for the six months ended June 30, 2022, representing an increase of about 195.7% from a loss of RMB 16.3 million for the same period in 2021, attributed to significant revenue and gross profit declines due to short-term lockdowns in multiple provinces in China[42]. - The loss before tax for the period was RMB (48,587) thousand, compared to RMB (14,415) thousand in 2021, reflecting a worsening financial performance[77]. - Total comprehensive loss for the period amounted to RMB (51,868) thousand, compared to a gain of RMB 9,137 thousand in the same period last year[77]. - Basic loss per share was RMB (24.88), a significant increase from RMB (9.01) in the previous year[77]. Expenses and Cost Management - Overall gross profit decreased from approximately RMB 35.8 million to RMB 17.3 million, with a slight decline in gross margin from 10.5% to 10.0%[33]. - Sales expenses decreased by approximately 2.9% from RMB 10.2 million to RMB 9.9 million, as the company implemented cost control measures in response to the significant drop in sales[35]. - Administrative expenses increased by approximately 2.6% from RMB 30.8 million for the six months ended June 30, 2021, to RMB 31.6 million for the six months ended June 30, 2022, primarily due to overall expansion-related office expenses[36]. - R&D expenses surged by 303.1%, rising from approximately RMB 6.4 million for the six months ended June 30, 2021, to RMB 25.8 million for the six months ended June 30, 2022, driven by projects in digital marketing solutions, digital healthcare solutions, and AI online platform development[37]. Cash Flow and Liquidity - Cash and bank balances decreased by 37.4%, from approximately RMB 165.3 million as of December 31, 2021, to approximately RMB 103.5 million as of June 30, 2022, reflecting the company's efforts to maintain optimal liquidity[55]. - The net cash used in operating activities for the six months ended June 30, 2022, was RMB (8,658) thousand, compared to RMB 2,023 thousand for the same period in 2021[90]. - The net cash used in investing activities amounted to RMB (50,887) thousand for the six months ended June 30, 2022, compared to RMB (47,743) thousand in 2021[90]. Assets and Liabilities - Total assets as of June 30, 2022, were RMB 342,592 thousand, down from RMB 366,700 thousand at the end of 2021[80]. - Current liabilities increased to RMB 90,050 thousand from RMB 57,270 thousand, indicating a rise in short-term financial obligations[84]. - The company's net assets decreased to RMB 244,578 thousand from RMB 293,487 thousand, reflecting a decline in overall financial health[84]. Shareholder Information and Equity - The total number of issued shares remained at 200,000,000 since the company's listing[60]. - The company’s major shareholders include Mr. Shi Zhuo, Mr. Yang Wei Min, and Ms. Zhang Yitao, collectively holding significant stakes[199]. - The total issued shares of the company as of June 30, 2022, were 200 million shares, with various shareholders holding substantial percentages[198]. Future Outlook - Revenue growth rates for the next five years are projected at 15%, 12%, 10%, 5%, and 2%, with a long-term growth rate of 2% beyond that period[139]. - The company plans to utilize approximately 58% of the net proceeds from its global offering to expand its customer base and disease coverage, 25% for developing internet hospital services, 12% for operational funds, and 5% for expanding CRO services[73].
麦迪卫康(02159) - 2022 - 中期财报